• Imfinzi Plus Chemo Extends Survival in Advanced Small Cell Lung Cancer, Trial Analysis Shows
  • Better Responses with IO102-Keytruda Combo Likely in Ongoing NSCLC Trial
  • Harbour BioMed Gets FDA Nod to Start US Trials of 2 Immunotherapies
  • FDA Approves Opdivo-Yervoy Combo for Previously Treated Liver Cancer
  • Phase 2 Trial of Probody-Opdivo Combo Expanding in Advanced Cancers
  • Imfinzi, Alone or in Combo, Fails at Survival Goals in Advanced Bladder Cancer Trial
  • 1st Patient Dosed in UK Trial of Anti-Cancer Virus TG6002
  • Cabiralizumab Plus Opdivo Failed to Halt Progression of Advanced Pancreatic Cancer, Trial Shows
  • Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare
  • Early Data Support Agenus’ 2 Lead Immunotherapies for Advanced Cervical Cancer
  • Researchers Develop Safer CAR T-cell That Can Be Temporarily Turned ‘Off’
  • First Patient Enrolled in Phase 1 Trial Investigating Galinpepimut-S and Opdivo for MPM